Effect of testosterone administration to men with prostate cancer is unpredictable: A word of caution and suggestions for a registry

BJU International

Volumn 107, Issue 9, 2011, Pages 1369-1373

  Morales, Alvaro ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b Centre for Applied Urological Research   (Canada)

Author keywords

androgens; prostate cancer; prostate safety; testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

ADULT; AGED; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ARTICLE; CANCER CELL; CANCER REGISTRY; CLINICAL ARTICLE; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; HUMAN; HYPOGONADISM; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANDROGENS; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES; TESTOSTERONE;

EID: 79955394539     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10193.x     Document Type: Article

References (22)

1. Hudson DL,. Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostatic Dis 2004; 7: 188-94 (Pubitemid 41741501)
2. Parsons JK, Palazzi-Churas K, Bergstrom J, Barrett-Connor E,. Prospective study of serum dehydrotestosterone and the subsequent risk of benign prostatic hyperplasia in community dwelling men: The Rancho Bernardo Study. J Urol 2010; 184: 1040-4
3. Huhtaniemi I, Pye SR, Limer K, et al,. Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats. J Clin Endocrinol Metab 2009; 94: 277-84
4. Lakshman KM, Kaplan B, Travison TG, et al,. The effect of injected testosterone dose and age in the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab 2010; 95: 3955-64
5. Marks LS, Mazer NA, Mostaghel E, et al,. Effect of testosterone replacement in therapy of prostate tissue in men with late onset hypogonadism. JAMA 2006; 296: 2351-62
6. Litvinov I, De Marzo AM, Isaacs JT,. The Achilles heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003; 88: 2972-82 (Pubitemid 36877458)
7. Huggins C, Hodges CV,. Studies on prostatic cancer 1. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7
8. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ,. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170-83 (Pubitemid 351480553)
9. Marks LS, Mostaghel EA, Nelson PS,. Prostate tissue androgens: history and current clinical relevance. Urology 2008; 72: 247-54
10. Morgentaler A,. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol 2009; 181: 972-9
11. Collier CP, Morales A, Clark A, Lam M, Wynne-Edwards K, Black A,. The significance of biological variation in the diagnosis of testosterone deficiency and consideration of the relevance of total, free and bioavailable testosterone determinations. J Urol 2010; 183: 2294-9
12. Bhasin S, Singh AB, Mac RP, Bellentine C, Martin IL, Cunningham GR,. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003; 24: 299-311 (Pubitemid 39571784)
13. Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S,. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts in androgen-stimulated phenotype in athymic mice. Cancer Res 2005; 65: 2082-4 (Pubitemid 40490112)
14. Morales A, Connolly JG, Bruce AW,. Androgen therapy in advanced carcinoma of the prostate. Can Med Assoc J 1971; 105: 71-3
15. Trunnel JB, Duffy BJ Jr,. The influence of certain steroids on the behavior of human prostatic cancer. Trans N Y Acad Sci 1950; 12: 238-41
16. Prout GR, Brewer WR,. Response of men with advanced prostate cancer to exogenous administration of testosterone. Cancer 1967; 20: 1871-8
17. Morgentaler A, Sweeney M, Bennett R, Avila D, Khera M, Lipshultz LI,. PSA and follow-up biopsy results in men who received testosterone therapy while on active surveillance for prostate cancer. J Urol 2010; 183 (Suppl. 4): e531; Abstr. 1376
18. Curran MJ, Bihrle W III,. Dramatic rise in prostatic specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999; 53: 423-4 (Pubitemid 29063343)
19. Klotz L, Boccon-Gibod L, Shore ND, et al,. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531-8
20. Svatek RS, Schulman MJ, Benaim EA, Rogers TE, Margulis E,. Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis. J Urol 2008; 179: 2192-5
21. Bhasin S, Cunningham G, Hayes F, et al,. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010; 95: 2536-59
22. Morales A, Black AM, Emerson LE,. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int 2009; 103: 62-4